Standard therapy for glioblastoma-a review of where we are

Neurologia Medico-Chirurgica

Volumn 50, Issue 9, 2010, Pages 713-719

  Nishikawa, Ryo ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Clinical trial; Glioblastoma; Standard therapy; Temozolomide

Indexed keywords

BETA INTERFERON; BEVACIZUMAB; CARMUSTINE; CILENGITIDE; CYCLOPHOSPHAMIDE; IRINOTECAN; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIMUSTINE; NITROSOUREA; PLACEBO; PLATINUM COMPLEX; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADJUVANT THERAPY; ARTICLE; BRACHYTHERAPY; BRAIN HEMORRHAGE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ABSORPTION; DRUG HALF LIFE; DRUG PENETRATION; EPISTAXIS; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; HUMAN; HYPERTENSION; INFECTION; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NATIONAL HEALTH ORGANIZATION; NEUROSURGERY; OVERALL SURVIVAL; PATIENT SAFETY; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; STEREOTACTIC BODY RADIATION THERAPY;

ANTINEOPLASTIC PROTOCOLS; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEUROSURGERY; PRACTICE GUIDELINES AS TOPIC;

EID: 77958097499     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.50.713     Document Type: Article

References (34)

1. Aoki T, Mizutani T, Nojima K, Takagi T, Okumura R, Yuba Y, Ueba T, Takahashi JA, Miyatake SI, Nozaki K, Taki W, Matsutani M: Phase II study of ifos- famide, carboplatin, and etoposide in patients with a first recurrent of glioblastoma multiforme. J Neu- rosurg 112: 50-56, 2010
2. Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G, Scopece L, Ferreri AJ, Panucci MG, Mon- fardini S, Ermani M: First-line chemotherapy with cisplatin plus fractionated temozolomide in recur- rent glioblastoma multiforme: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol 22: 1598-1604, 2004
3. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Sou- hami L, Laperierre N, Mehta M, Curran W: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplas- tic oligodendroglioma: Intergroup Radiation Ther- apy Oncology Group trial 9402. J Clin Oncol 24: 2707-2714, 2006
4. Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, Souhami L, Chen A, Pham H, Mehta M: A phase II trial of accelerated radiother- apy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 65: 1422-1428, 2006
5. Chamberian MC, Tsao-Wei DD, Groshen S: Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer 106: 172-179, 2006
6. Fischer I, Cunliffe CH, Bollo RJ, Raza S, Monoky D, Chiriboga L, Parker EC, Golfinos JG, Kelly PJ, Knopp EA, Gruber ML, Zagzag D, Narayana A: High-grade glioma before and after treatment with radiation and Avastin: Initial observations. Neuro Oncol 10: 700-708, 2008
7. Franceschi E, Cavallo G, Scopece L, Paioli A, Pession A, Magrini E, Conforti R, Palmerini E, Bartolini S, Rimondinin S, Esposti RD, Crino L: Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br J Cancer 91: 1038-1044, 2004
8. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WKA, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin On- col 27: 4733-4740, 2009
9. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR: Correlation of O6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26: 4189-4199, 2008
10. Keime-Guibert F, Chinot O, Taillandier L, Cartalat- Carel S, Frenay M, Kantor G, Guillamo JS, Jadau E, Colin P, Bondiau PY, Menei P, Loiseau H, Bernier V, Honnorat J, Barrie M, Mokhtari K, Mazeron JJ, Bis- sey A, Delattre JY: Radiotherapy for glioblastoma in the elderly. N Engl J Med 356: 1527-1535, 2007
11. Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, Tofilon PJ, Camphausen K: In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 14: 931-938, 2008
12. Medical Research Council Brain Tumour Working Party: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high- grade astrocytoma: a Medical Research Council trial. J Clin Oncol 19: 509-518, 2001
13. Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P, Eagan P, Gruber ML: Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 110: 173-180, 2009
14. National Cancer Institute: Dictionary of Cancer Terms. Available from: http://www.cancer.gov/ dictionary/?Cdr1D=44930
15. National Cancer Institute: Physician Data Query. Available from: http://www.cancer.gov/cancertopics/ pdq
16. Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hata- no H, Mizuno M, Yoshida J: IFN-β down-regulates the expression of DNA repair gene MGMT and sensi- tizes resistant glioma cells to temozolomide. Cancer Res 65: 7573-7579, 2005
17. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B Drappatz J, Kesari S, Wen PY: Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787, 2008
18. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sul- man EP, Bhat KP, Verhaak RGW, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Ban Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Al-dape K: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522, 2010
19. Paez-Ribes M, Allen E, Hudock J, Takeda T, Ouyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O: Antiangiogenic therapy elicits malig- nant progression of tumors to increased local inva- sion and distant metastasis. Cancer Cell 15: 220-231, 2009
20. Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisen- stat DD, Thiessen B, Forsyth P, Pouliot JF: Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28: 2051-2057, 2010
21. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of ad- juvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12: 116-121, 2010
22. Roa W, Brasher PMA, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, Husain S, Murtha A, Petruk K, Stewart D, Tai P, Ur- tasun R, Cairncross JG, Forsyth P: Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial. J Clin Oncol 22: 1583-1588, 2004
23. Selker RG, Shapiro WR, Burger P, Blackwood M, Deutsch M, Arena VC, Van Gilder JC, Wu J, Malkin MG, Mealey J Jr, Neal JH, Olson J, Robertson JT, Bar- nett GH, Bloomfield S, Albright R, Hochberg FH, Hiesiger E, Green S: The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine ver- sus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51: 343-357, 2002
24. Souliotis VL, Kaila S, Boussiotis VA, Pangalis GA, Kyrtopoulos SA: Accumulation of O6-methylguanine in human blood leukocyte DNA during exposure to procarbazine and its relationships with dose and repair. Cancer Res 50: 2759-2764, 1990
25. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B,Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer R, Lud- win SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for gliob- lastoma. N Engl J Med 352: 987-996, 2005
26. Takakura K, Abe H, Tanaka R, Kitamura K, Miwa T, Takeuchi K, Yamamoto S, Kageyama N, Handa H, Mogami H, Nishimoto A, Uozumi T, Matsutani M, Nomura K: Effects of ACNU and radiotherapy on malignant glioma. J Neurosurg 64: 53-57, 1986
27. Tolcher AW, Gerson SL, Denis L, Geyer C, Ham- mond LA, Patnaik A, Goetz AD, Schwartz G, Ed- wards T, Reyderman L, Statkevich P, Cutier DL, Rowinsky EK: Marked inactivation of O6-alkyl- guanine-DNA alkyltransferase activity with protract-ed temozolomide schedules. Br J Cancer88: 1004-1011, 2003
28. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M,Taphoorn MJB, Bernsen HJJA, Frenay M. Tijssen CC, Grisold W. Sipos L, Haaxima-Reiche H, Kros Lacombe D, Gorlia T: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocyto- mas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24: 2715-2722, 2006
29. Vinjamuri M, Adumala RR, Altaha R, Hobbs GR, Crowell EB Jr: Comparative analysis of temozolomide (TMZ) versus 1,3-bis(2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme(GBM) patients. J Neurooncol 91: 221-225, 2009
30. Vrendenburgh JJ, Desjardins A, Herndon JE, Marcel- lo J, Reardon DA, Quinn JA, Rich JN, Sathornsume- tee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Sriedman HS: Bevacizumab plus irinotecan in recurrent glioblasto- ma multiforme. J Clin Oncol 25: 4722-4729, 2007
31. Wang CH, Li J, Teo CS, Lee T: The delivery of BCNU to brain tumors. J Controlled Release 61: 21-41, 1999
32. ® wafer in initial surgery for malignant glio- ma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 148: 269-275, 2006
33. Wick A, Pascher C, Wick W, Jauch T, Weller M, Bog-dahn U, Hau P: Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 256: 734-741, 2009
34. Yung WKA, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588-593, 2000